Table 1. Comparison of biological and clinical characteristics in groups of patients treated with pemetrexed plus platinum as first-line chemotherapy and stratified by expression levels of thymidylate synthase, excision repair cross-complementation group 1, or astrocyte-elevated gene-1 proteins.
| Low TS vs. high TS n (%) |
P value | Low ERCC1 vs. high ERCC1 n (%) |
P value | Low AEG-1 vs. high AEG-1 n (%) |
P value | |
|---|---|---|---|---|---|---|
| Age | ||||||
| < 60 (n = 37) | 22 (59.5%) vs. 15 (40.5%) |
0.293 | 20(54.1%) vs. 17 (45.9%) |
0.722 | 22 (59.5%) vs. 15 (40.5%) |
0.293 |
| ≥ 60 (n = 40) | 19 (47.5%) vs. 21 (52.5%) |
20 (50.0%) vs. 20 (50.0%) |
19 (47.5%) vs. 21 (52.5%) |
|||
| Gender | ||||||
| Male (n = 42) | 26 (61.9%) vs. 16 (38.1%) |
0.095 | 26 (61.9%) vs. 16 (38.1%) |
0.055 | 24 (57.1%) vs. 18 (42.9%) |
0.453 |
| Female (n = 35) | 15 (42.9%) vs. 20 (57.1%) |
14 (40.0%) vs. 21 (60.0%) |
17 (48.6%) vs. 18 (51.4%) |
|||
| Smoking | ||||||
| Never (n = 26) | 15 (57.7%) vs. 11 (42.3%) |
0.577 | 14(53.8%) vs. 12 (46.2%) |
0.812 | 14(53.8%) vs. 12 (46.2%) |
0.940 |
| Current or ever (n= 51) | 26 (51.0%) vs. 25 (49.0%) |
26 (51.0%) vs. 25 (49.0%) |
27 (52.9%) vs. 24 (47.1%) |
|||
| Stage | ||||||
| IIB (n = 19) | 10 (52.6%) vs. 9 (47.4%) |
0.951 | 12 (63.2%) vs. 7 (36.8%) |
0.260 | 9 (47.4%) vs. 10 (52.6%) |
0.554 |
| IV (n = 58) | 31 (53.4%) vs. 27 (46.6%) |
28 (48.3%) vs. 30 (51.7%) |
32 (55.2%) vs. 26 (44.8%) |
|||
| Treatment response | ||||||
| PR (n = 38) | 22 (57.9%) vs. 16 (42.1%) |
0.04 | 22 (57.9%) vs. 16 (42.1%) |
0.088 | 23 (60.5%) vs. 15 (39.5%) |
0.206 |
| SD or PD (n = 39) | 14 (35.9%) vs. 25 (64.1%) |
15 (38.4%) vs. 24 (61.5%) |
18 (36.2%) vs. 21 (53.8%) |
|||
AEG-1, astrocyte-elevated gene-1; ERCC1, excision repair cross-complementation group 1; PD, progressive disease; PR, partial response; SD, stable disease; TS, thymidylate synthase